196 related articles for article (PubMed ID: 30508617)
1. Worse Outcomes for Head and Neck Rhabdomyosarcoma Secondary to Reduced-Dose Cyclophosphamide.
Casey DL; Wexler LH; Wolden SL
Int J Radiat Oncol Biol Phys; 2019 Apr; 103(5):1151-1157. PubMed ID: 30508617
[TBL] [Abstract][Full Text] [Related]
2. Disease Control and Patterns of Failure After Proton Beam Therapy for Rhabdomyosarcoma.
Buszek SM; Ludmir EB; Grosshans DR; McAleer MF; McGovern SL; Harrison DJ; Okcu MF; Chintagumpala MM; Mahajan A; Paulino AC
Int J Radiat Oncol Biol Phys; 2021 Mar; 109(3):718-725. PubMed ID: 33516439
[TBL] [Abstract][Full Text] [Related]
3. Volumetric considerations in radiotherapy for pediatric parameningeal rhabdomyosarcomas.
Chen C; Shu HK; Goldwein JW; Womer RB; Maity A
Int J Radiat Oncol Biol Phys; 2003 Apr; 55(5):1294-9. PubMed ID: 12654440
[TBL] [Abstract][Full Text] [Related]
4. Parameningeal rhabdomyosarcoma: outcomes and opportunities.
Yang JC; Wexler LH; Meyers PA; Wolden SL
Int J Radiat Oncol Biol Phys; 2013 Jan; 85(1):e61-6. PubMed ID: 23021437
[TBL] [Abstract][Full Text] [Related]
5. Proton radiotherapy for parameningeal rhabdomyosarcoma: clinical outcomes and late effects.
Childs SK; Kozak KR; Friedmann AM; Yeap BY; Adams J; MacDonald SM; Liebsch NJ; Tarbell NJ; Yock TI
Int J Radiat Oncol Biol Phys; 2012 Feb; 82(2):635-42. PubMed ID: 21377294
[TBL] [Abstract][Full Text] [Related]
6. Patterns of failure and toxicity profile following proton beam therapy for pediatric bladder and prostate rhabdomyosarcoma.
Buszek SM; Ludmir EB; Grosshans DR; McAleer MF; McGovern SL; Harrison DJ; Okcu MF; Chintagumpala MM; Mahajan A; Paulino AC
Pediatr Blood Cancer; 2019 Nov; 66(11):e27952. PubMed ID: 31397065
[TBL] [Abstract][Full Text] [Related]
7. Intensity-modulated radiotherapy with use of cone-down boost for pediatric head-and-neck rhabdomyosarcoma.
McDonald MW; Esiashvili N; George BA; Katzenstein HM; Olson TA; Rapkin LB; Marcus RB
Int J Radiat Oncol Biol Phys; 2008 Nov; 72(3):884-91. PubMed ID: 18455321
[TBL] [Abstract][Full Text] [Related]
8. The challenging role of radiation therapy for very young children with rhabdomyosarcoma.
Puri DR; Wexler LH; Meyers PA; La Quaglia MP; Healey JH; Wolden SL
Int J Radiat Oncol Biol Phys; 2006 Jul; 65(4):1177-84. PubMed ID: 16682130
[TBL] [Abstract][Full Text] [Related]
9. Delayed radiotherapy following dose intensive chemotherapy for parameningeal rhabdomyosarcoma (PM-RMS) of childhood.
Douglas JG; Arndt CA; Hawkins DS
Eur J Cancer; 2007 Apr; 43(6):1045-50. PubMed ID: 17368885
[TBL] [Abstract][Full Text] [Related]
10. Local control with reduced-dose radiotherapy for low-risk rhabdomyosarcoma: a report from the Children's Oncology Group D9602 study.
Breneman J; Meza J; Donaldson SS; Raney RB; Wolden S; Michalski J; Laurie F; Rodeberg DA; Meyer W; Walterhouse D; Hawkins DS
Int J Radiat Oncol Biol Phys; 2012 Jun; 83(2):720-6. PubMed ID: 22104356
[TBL] [Abstract][Full Text] [Related]
11. Effect of radiotherapy techniques (IMRT vs. 3D-CRT) on outcome in patients with intermediate-risk rhabdomyosarcoma enrolled in COG D9803--a report from the Children's Oncology Group.
Lin C; Donaldson SS; Meza JL; Anderson JR; Lyden ER; Brown CK; Morano K; Laurie F; Arndt CA; Enke CA; Breneman JC
Int J Radiat Oncol Biol Phys; 2012 Apr; 82(5):1764-70. PubMed ID: 21470795
[TBL] [Abstract][Full Text] [Related]
12. Patterns of failure following proton beam therapy for head and neck rhabdomyosarcoma.
Ludmir EB; Grosshans DR; McAleer MF; McGovern SL; Harrison DJ; Okcu MF; Chintagumpala MM; Mahajan A; Paulino AC
Radiother Oncol; 2019 May; 134():143-150. PubMed ID: 31005208
[TBL] [Abstract][Full Text] [Related]
13. [Rhabdomyosarcoma in middle to old-aged patients: analysis of clinicopathological features and prognosis in 76 cases].
Yu L; Wang J
Zhonghua Zhong Liu Za Zhi; 2012 Dec; 34(12):910-6. PubMed ID: 23336377
[TBL] [Abstract][Full Text] [Related]
14. Local Control for Intermediate-Risk Rhabdomyosarcoma: Results From D9803 According to Histology, Group, Site, and Size: A Report From the Children's Oncology Group.
Wolden SL; Lyden ER; Arndt CA; Hawkins DS; Anderson JR; Rodeberg DA; Morris CD; Donaldson SS
Int J Radiat Oncol Biol Phys; 2015 Dec; 93(5):1071-6. PubMed ID: 26581144
[TBL] [Abstract][Full Text] [Related]
15. Reduction of cyclophosphamide dose for patients with subset 2 low-risk rhabdomyosarcoma is associated with an increased risk of recurrence: A report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group.
Walterhouse DO; Pappo AS; Meza JL; Breneman JC; Hayes-Jordan A; Parham DM; Cripe TP; Anderson JR; Meyer WH; Hawkins DS
Cancer; 2017 Jun; 123(12):2368-2375. PubMed ID: 28211936
[TBL] [Abstract][Full Text] [Related]
16. Outcome and Patterns of Relapse in Childhood Parameningeal Rhabdomyosarcoma Treated With Proton Beam Therapy.
Doyen J; Jazmati D; Geismar D; Frisch S; Schleithoff SS; Vermeren X; Scheer M; Blase C; Tippelt S; Timmermann B
Int J Radiat Oncol Biol Phys; 2019 Dec; 105(5):1043-1054. PubMed ID: 31419513
[TBL] [Abstract][Full Text] [Related]
17. Regional Nodal Control for Head and Neck Alveolar Rhabdomyosarcoma.
Ludmir EB; Paulino AC; Grosshans DR; McAleer MF; McGovern SL; Huh WW; Okcu MF; Harrell LM; Mahajan A
Int J Radiat Oncol Biol Phys; 2018 May; 101(1):169-176. PubMed ID: 29477293
[TBL] [Abstract][Full Text] [Related]
18. 45 GyRBE for group III orbital embryonal rhabdomyosarcoma.
Indelicato DJ; Rotondo RL; Mailhot Vega RB; Uezono H; Bradfield S; Agarwal V; Hol ML; Bradley JA
Acta Oncol; 2019 Oct; 58(10):1404-1409. PubMed ID: 31530120
[No Abstract] [Full Text] [Related]
19. Vinorelbine and continuous low-dose cyclophosphamide as maintenance chemotherapy in patients with high-risk rhabdomyosarcoma (RMS 2005): a multicentre, open-label, randomised, phase 3 trial.
Bisogno G; De Salvo GL; Bergeron C; Gallego Melcón S; Merks JH; Kelsey A; Martelli H; Minard-Colin V; Orbach D; Glosli H; Chisholm J; Casanova M; Zanetti I; Devalck C; Ben-Arush M; Mudry P; Ferman S; Jenney M; Ferrari A;
Lancet Oncol; 2019 Nov; 20(11):1566-1575. PubMed ID: 31562043
[TBL] [Abstract][Full Text] [Related]
20. Local control after intensity-modulated radiotherapy for head-and-neck rhabdomyosarcoma.
Curtis AE; Okcu MF; Chintagumpala M; Teh BS; Paulino AC
Int J Radiat Oncol Biol Phys; 2009 Jan; 73(1):173-7. PubMed ID: 18501529
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
